STIEPROX SHAMPOO

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

CICLOPIROX OLAMINE

Dostopno od:

GLAXOSMITHKLINE INC

Koda artikla:

D01AE14

INN (mednarodno ime):

CICLOPIROX

Odmerek:

1.5%

Farmacevtska oblika:

SHAMPOO

Sestava:

CICLOPIROX OLAMINE 1.5%

Pot uporabe:

TOPICAL

Enote v paketu:

10ML/100ML

Tip zastaranja:

Prescription

Terapevtsko območje:

HYDROXYPYRIDONES

Povzetek izdelek:

Active ingredient group (AIG) number: 0115999002; AHFS:

Status dovoljenje:

CANCELLED POST MARKET

Datum dovoljenje:

2024-01-31

Lastnosti izdelka

_ _
_September 08, 2014 _
_ _
_Page 1 of 23_
PRODUCT MONOGRAPH
Pr
STIEPROX
®
ciclopirox olamine (shampoo) 1.5% w/w
Topical Antifungal
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
www.stiefel.ca
Date of Revision:
September 8, 2014
Submission Control No: 168647
_©_
_ 2014 GlaxoSmithKline Inc. All Rights Reserved _
_ _
_®_
_STIEPROX is_
_a registered trade-mark, used under license by GlaxoSmithKline Inc. _
_ _
_September 08, 2014 _
_ _
_Page 2 of 23_
TABLE OF CONTENTS
PAGE
PART I: HEALTH PROFESSIONAL INFORMATION ................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
...........................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE REACTIONS
............................................................................................
5
DRUG INTERACTIONS
............................................................................................
6
DOSAGE AND ADMINISTRATION
..........................................................................
7
OVERDOSAGE
.........................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 8
STORAGE AND STABILITY
.....................................................................................
8
SPECIAL HANDLING INSTRUCTIONS
.................................................................... 8
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 8
PART II: SCIENTIFIC INFORMATION ......................................................................
10
PHARMACEUTICAL INFORMATION
........................................................